Funko Inc vs Sana Biotechnology Inc — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 2.3× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Sana Biotechnology Inc for 23 Days on average.
| FNKO | SANA | |
|---|---|---|
Market Cap | $363.97M | $836.71M |
Volume | 1,422,651 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $5.92 |
52-Week Low | $2.81 | $2.68 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $584.62M | $749.96M |
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.44, up 2.06% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst sentiment is mixed with a 'Hold' consensus and $7.58 price target, representing 17.7% upside potential from current levels.
Investment outlook balances operational improvements against persistent profitability challenges. The stock offers potential upside from continued execution of the 'Make Culture POP!' strategy and margin expansion, but faces risks from consumer discretionary spending volatility and competitive pressures in the collectibles market.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →